Published in Dement Geriatr Cogn Disord on February 13, 2008
Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. J Neural Transm (Vienna) (2009) 1.10
Cerebrospinal fluid levels of tau phosphorylated at threonine 181 in patients with Alzheimer's disease and vascular dementia. Neurol Sci (2008) 0.86
Dkk-3 is elevated in CSF and plasma of Alzheimer's disease patients. J Neurochem (2009) 0.86
cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases. Int J Alzheimers Dis (2010) 0.84
Biomarkers for early diagnosis of Alzheimer disease: 'ALZheimer ASsociated gene'--a new blood biomarker? J Cell Mol Med (2008) 0.82
Combined Analysis of CSF Tau, Aβ42, Aβ1-42% and Aβ1-40% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia. Int J Alzheimers Dis (2010) 0.78
Does CSF p-tau181 help to discriminate Alzheimer's disease from other dementias and mild cognitive impairment? A meta-analysis of the literature. J Neural Transm (Vienna) (2014) 0.77
Neurochemical biomarkers in Alzheimer's disease and related disorders. Ther Adv Neurol Disord (2012) 0.76
CSF biomarkers and neuropsychological profiles in patients with cerebral small-vessel disease. PLoS One (2014) 0.75
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
The UniProt-GO Annotation database in 2011. Nucleic Acids Res (2011) 5.19
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12
A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet (2011) 4.52
Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med (2006) 4.16
Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med (2002) 3.87
Hippocampal plasticity in response to exercise in schizophrenia. Arch Gen Psychiatry (2010) 3.42
Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem (2006) 3.03
Distinctive neurocognitive effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy in major depression. Br J Psychiatry (2005) 2.84
The mechanism of γ-Secretase dysfunction in familial Alzheimer disease. EMBO J (2012) 2.72
Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement (2010) 2.68
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Proc Natl Acad Sci U S A (2003) 2.54
Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology (2013) 2.47
The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res (2010) 2.45
microRNA-34c is a novel target to treat dementias. EMBO J (2011) 2.44
gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science (2009) 2.43
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol (2011) 2.41
MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord (2011) 2.27
A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status. Crit Care Med (2009) 2.20
GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proc Natl Acad Sci U S A (2008) 2.17
Associated factors for REM sleep behavior disorder in Parkinson disease. Neurology (2011) 2.17
Socioeconomic status and depression during and after pregnancy in the Franconian Maternal Health Evaluation Studies (FRAMES). Arch Gynecol Obstet (2013) 2.06
MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro Oncol (2012) 2.02
Fear is only as deep as the mind allows: a coordinate-based meta-analysis of neuroimaging studies on the regulation of negative affect. Neuroimage (2011) 2.02
CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement (2013) 1.90
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement (2011) 1.85
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol (2013) 1.84
Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol (2013) 1.83
Managing an effective treatment for neuroleptic malignant syndrome. Crit Care (2007) 1.73
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry (2012) 1.69
Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet (2013) 1.68
Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J Biol Psychiatry (2009) 1.64
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry (2012) 1.55
Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. Clin Chem (2006) 1.54
Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology (2013) 1.53
Deficient inhibitory cortical networks in antipsychotic-naive subjects at risk of developing first-episode psychosis and first-episode schizophrenia patients: a cross-sectional study. Biol Psychiatry (2012) 1.53
Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. J Neurochem (2012) 1.52
Use-dependent inhibition of synaptic transmission by the secretion of intravesicularly accumulated antipsychotic drugs. Neuron (2012) 1.51
Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium. Acta Neuropathol (2008) 1.51
Epigenetic DNA hypermethylation of the HERP gene promoter induces down-regulation of its mRNA expression in patients with alcohol dependence. Alcohol Clin Exp Res (2006) 1.51
Homocysteine metabolism and cerebrospinal fluid markers for Alzheimer's disease. J Alzheimers Dis (2009) 1.49
Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Cogn Disord (2006) 1.49
Serum levels of the Th1 chemoattractant interferon-gamma-inducible protein (IP) 10 are elevated in patients with essential hypertension. Hypertens Res (2011) 1.49
Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol Aging (2004) 1.48
Polysomnographic findings, video-based sleep analysis and sleep perception in progressive supranuclear palsy. Sleep Med (2008) 1.48
Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med (2012) 1.48
DNA hypermethylation of the alpha synuclein promoter in patients with alcoholism. Neuroreport (2005) 1.46
Drug-induced psychosis after long-term treatment with levetiracetam. Can J Psychiatry (2004) 1.46
Repetitive transcranial magnetic stimulation influences mood in healthy male volunteers. J Psychiatr Res (2011) 1.46
An integrated theory of whole number and fractions development. Cogn Psychol (2011) 1.46
Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls. World J Biol Psychiatry (2010) 1.45
The role of the human ventral striatum and the medial orbitofrontal cortex in the representation of reward magnitude - an activation likelihood estimation meta-analysis of neuroimaging studies of passive reward expectancy and outcome processing. Neuropsychologia (2012) 1.44
Precipitation driven decadal scale decline and recovery of wetlands of Lake Pannon during the Tortonian. Palaeogeogr Palaeoclimatol Palaeoecol (2012) 1.42
Catheter ablation of left atrial focal tachycardia guided by electroanatomic mapping and new insights into interatrial electrical conduction. Heart Rhythm (2005) 1.41
The herpes simplex virus type 1 U(S)11 protein interacts with protein kinase R in infected cells and requires a 30-amino-acid sequence adjacent to a kinase substrate domain. J Virol (2002) 1.41
Decreased plasma cholesterol levels during aging in transgenic mouse models of Alzheimer's disease. Exp Gerontol (2005) 1.39
[The confused patient]. MMW Fortschr Med (2014) 1.38
Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugs. Nat Med (2013) 1.36
A review and new report of medial temporal lobe dysfunction as a vulnerability indicator for schizophrenia: a magnetic resonance imaging morphometric family study of the parahippocampal gyrus. Schizophr Bull (2003) 1.34
Therapeutic approaches to Alzheimer's disease. Brain (2006) 1.34
Effects of antipsychotics on brain structure. Curr Opin Psychiatry (2006) 1.33
Global DNA methylation is influenced by smoking behaviour. Eur Neuropsychopharmacol (2008) 1.29
Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. J Neurochem (2007) 1.28
Biatrial multisite mapping of atrial premature complexes triggering onset of atrial fibrillation. Am J Cardiol (2002) 1.28
Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides. Electrophoresis (2004) 1.27
International quality control survey of neurochemical dementia diagnostics. Neurosci Lett (2006) 1.26
Functional neuroimaging of reward processing and decision-making: a review of aberrant motivational and affective processing in addiction and mood disorders. Brain Res Rev (2008) 1.25
Retrieval of the Alzheimer's amyloid precursor protein from the endosome to the TGN is S655 phosphorylation state-dependent and retromer-mediated. Mol Neurodegener (2010) 1.25
CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain (2006) 1.25
Genetic load on amygdala hypofunction during sadness in nonaffected brothers of schizophrenia patients. Am J Psychiatry (2004) 1.24